Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4948807	NOVARTIS	Phenyl carbamates	Aug, 2012 (11 years ago)
US5602176	NOVARTIS	Phenyl carbamate	Feb, 2014 (10 years ago)

Exelon is owned by Novartis.

Exelon contains Rivastigmine Tartrate.

Exelon has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Exelon are:

Exelon was authorised for market use on 21 April, 2000.

Exelon is available in solution;oral, capsule;oral dosage forms.

Exelon can be used as treatment of alzheimer's dementia.

The generics of Exelon are possible to be released after 11 February, 2014.

Market Authorisation Date: 21 April, 2000

Treatment: Treatment of alzheimer's dementia

Dosage: SOLUTION;ORAL; CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1.5 mg, 3 mg, 4.5 mg and 6 mg	21 Apr, 2004	3	22 Oct, 2007	11 Feb, 2014	Eligible
2 mg/mL	05 Nov, 2004	1		11 Feb, 2014	Extinguished

Strength	Dosage	Availability
EQ 2MG BASE/ML	SOLUTION;ORAL	Discontinued
EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued

EXELON family patents

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4948807	SANDOZ	Phenyl carbamates	Aug, 2012 (11 years ago)
US5602176	SANDOZ	Phenyl carbamate	Feb, 2014 (10 years ago)
US6335031	SANDOZ	TTS containing an antioxidant	Jan, 2019 (5 years ago)
US6316023	SANDOZ	TTS containing an antioxidant	Jan, 2019 (5 years ago)

Exelon is owned by Sandoz.

Exelon contains Rivastigmine.

Exelon has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Exelon are:

Exelon was authorised for market use on 06 July, 2007.

Exelon is available in film, extended release;transdermal dosage forms.

Exelon can be used as treatment of alzheimer's dementia.

The generics of Exelon are possible to be released after 08 January, 2019.

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 27, 2016
New Strength(NS)	Aug 31, 2015

Market Authorisation Date: 06 July, 2007

Treatment: Treatment of alzheimer's dementia

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4.6 mg/24 hr and 9.5 mg/24 hr	27 Apr, 2011	1		08 Jan, 2019	Extinguished
13.3 mg/24 hr	22 Jan, 2013	1	31 Aug, 2015	08 Jan, 2019	Eligible

Strength	Dosage	Availability
9.5MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
4.6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
13.3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription